AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) Director Wesley Johnson sold 6,201 shares of the company’s stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $23.00, for a total transaction of $142,623.00. Following the completion of the sale, the director now owns 80,003 shares in the company, valued at approximately $1,840,069. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ ANGO traded up $0.03 during mid-day trading on Wednesday, reaching $23.12. The company’s stock had a trading volume of 10,905 shares, compared to its average volume of 322,294. The stock has a 50-day moving average of $22.48 and a two-hundred day moving average of $24.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.61 and a current ratio of 2.59. The stock has a market capitalization of $895.14 million, a P/E ratio of -22.49 and a beta of 0.93. AngioDynamics, Inc. has a 1-year low of $20.03 and a 1-year high of $32.00.
AngioDynamics (NASDAQ:ANGO – Get Rating) last released its quarterly earnings data on Thursday, April 7th. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. AngioDynamics had a negative net margin of 12.99% and a negative return on equity of 0.12%. The company had revenue of $74.00 million during the quarter, compared to the consensus estimate of $76.32 million. During the same quarter in the prior year, the firm earned $0.02 EPS. AngioDynamics’s quarterly revenue was up 3.9% on a year-over-year basis. Analysts predict that AngioDynamics, Inc. will post -0.01 EPS for the current fiscal year.
Several equities research analysts recently issued reports on ANGO shares. Zacks Investment Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating and set a $21.00 target price for the company. in a report on Tuesday, March 8th. StockNews.com assumed coverage on AngioDynamics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group increased their target price on shares of AngioDynamics from $34.00 to $40.00 in a research report on Friday, April 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.50.
AngioDynamics Company Profile (Get Rating)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.